{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:51:27Z","timestamp":1774313487488,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>There is still no consensus on the significance of Lymphadenectomy (LD) and the number of lymph nodes that need to be excised (ELNs) for adequate LD in patients with early-stage primary fallopian tube cancer (PFTC). Our endeavor is geared towards deepening comprehension of LD in early-stage PFTC and identify the optimal cut-off of ELNs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This SEER-based study analyzed the clinical data of patients with early-stage PFTC between 2000 and 2018. X-tile was employed to confirm the optimal cut-off of ELNs. The survival data between groups were analyzed by the Kaplan-Meier estimates, Log-rank test and Cox proportional hazards model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was significant improvement in both mean cancer-specific survival (CSS, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and overall survival (OS, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in LD group. Regardless of matched or not, LD was identified as an independent protective factor of CSS and OS. The optimal 3-year CSS-based cutoff of ELNs was 11 (<jats:italic>p<\/jats:italic>\u2009=\u20090.026) as determined by X-tile. Both the mean CSS (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and mean OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) in adequate LD group (ELNs\u2009&gt;\u200911, <jats:italic>n<\/jats:italic>\u2009=\u2009574) were significantly longer than these in inadequate LD group (ELNs\u2009\u2264\u200911, <jats:italic>n<\/jats:italic>\u2009=\u2009738). Adequate LD, FIGO stage, tumor grade and histology were significant prognostic factors for CSS and OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LD is an independent protective prognostic factor of patients with early-stage PFTC. The association between ELNs\u2009&gt;\u200911 and an improved prognosis is evident. Future studies are needed to further clarify the results above.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-023-02833-y","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:02:17Z","timestamp":1703163737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphadenectomy and optimal excise lymph nodes count for early-stage primary fallopian tube cancer: a SEER-based study"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuexi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanfan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingmiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-3035","authenticated-orcid":false,"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-4843","authenticated-orcid":false,"given":"Yao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"2","key":"2833_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejogrb.2013.03.023","volume":"169","author":"E Kalampokas","year":"2013","unstructured":"Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):155\u201361.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"2833_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"key":"2833_CR3","volume-title":"Abdomen and Pelvis: Female Internal Genitals","author":"BS Hoare","year":"2023","unstructured":"Hoare BS, Khan YS, Anatomy. Abdomen and Pelvis: Female Internal Genitals. Treasure Island: StatPearls; 2023."},{"issue":"5","key":"2833_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.tjog.2019.07.008","volume":"58","author":"M Sun","year":"2019","unstructured":"Sun M, Bao L, Shen H, Ji M, Yao L, Yi X, et al. Unexpected primary fallopian tube carcinoma during gynecological operations: clinicopathological and prognostic factors analyses of 67 cases. Taiwan J Obstet Gynecol. 2019;58(5):626\u201332.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2833_CR5","doi-asserted-by":"crossref","unstructured":"Borghese M, Vizzielli G, Capelli G, Santoro A, Angelico G, Arciuolo D, et al. Retrospective study of histopathological and prognostic characteristics of primary fallopian tube carcinomas: twenty-year experience (SOCRATE). Int J Gynecol Cancer. 2022.","DOI":"10.1136\/ijgc-2022-003468"},{"issue":"3","key":"2833_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10147-010-0030-4","volume":"15","author":"N Sakurai","year":"2010","unstructured":"Sakurai N, Tateoka K, Fukaya K, Terada T, Kubushiro K. Supraclavicular lymph node Metastasis as the initial presentation of primary fallopian tube carcinoma. Int J Clin Oncol. 2010;15(3):301\u20134.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2833_CR7","first-page":"22","volume":"22","author":"P Benedetti Panici","year":"2020","unstructured":"Benedetti Panici P, Giannini A, Fischetti M, Lecce F, Di Donato V. Lymphadenectomy in Ovarian Cancer: Is It Still Justified? Current Oncology Reports. 2020;22(3):22.","journal-title":"Lymphadenectomy in Ovarian Cancer: Is It Still Justified? Current Oncology Reports"},{"issue":"Suppl 24","key":"2833_CR8","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1002\/cncr.32514","volume":"125","author":"P Harter","year":"2019","unstructured":"Harter P, Heitz F, Ataseven B, Schneider S, Baert T, Prader S, et al. How to manage lymph nodes in Ovarian cancer. Cancer. 2019;125(Suppl 24):4573\u20137.","journal-title":"Cancer"},{"issue":"9","key":"2833_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019;380(9):822\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"2833_CR10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.3802\/jgo.2023.34.e52","volume":"34","author":"T Deng","year":"2023","unstructured":"Deng T, Liu K, Chen L, Chen X, Li HW, Guo H, et al. A prospective randomized multicenter trial for lymphadenectomy in early-stage Ovarian cancer: LOVE study. J Gynecologic Oncol. 2023;34(3):e52.","journal-title":"J Gynecologic Oncol"},{"issue":"1","key":"2833_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320.","journal-title":"Clin Kidney J"},{"issue":"3","key":"2833_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/IGC.0000000000000648","volume":"26","author":"L Bao","year":"2016","unstructured":"Bao L, Ding Y, Cai Q, Ning Y, Hu W, Xue X, et al. Primary fallopian tube carcinoma: a single-Institution experience of 101 cases: a retrospective study. Int J Gynecol cancer. 2016;26(3):424\u201330.","journal-title":"Int J Gynecol cancer."},{"issue":"4","key":"2833_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"Cancer J Clin"},{"issue":"8","key":"2833_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1634\/theoncologist.11-8-902","volume":"11","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006;11(8):902\u201312.","journal-title":"Oncologist"},{"issue":"6","key":"2833_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/08941939.2022.2048142","volume":"35","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Liu YX, Li RN, Wei X, Wang QM, Gu QY, et al. Lymphadenectomy in primary fallopian tube Cancer is Associated with Improved Survival. J Invest Surgery: Official J Acad Surg Res. 2022;35(6):1417\u201323.","journal-title":"J Invest Surgery: Official J Acad Surg Res"},{"issue":"3","key":"2833_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1245\/s10434-009-0819-4","volume":"17","author":"N Solomon","year":"2010","unstructured":"Solomon N, Zhuge Y, Cheung M, Franceschi D, Koniaris LG. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2010;17(3):791\u2013803.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2833_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: Colon Cancer, Version 2.2018. J Natl Compr Cancer Network: JNCCN. 2018;16(4):359\u201369.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"2833_CR18","doi-asserted-by":"publisher","first-page":"696732","DOI":"10.3389\/fonc.2021.696732","volume":"11","author":"Q Chen","year":"2021","unstructured":"Chen Q, Li M, Wang P, Chen J, Zhao H, Zhao J. Optimal cut-off values of the positive lymph node ratio and the number of removed nodes for patients receiving resection of Bronchopulmonary carcinoids: a propensity score-weighted analysis of the SEER database. Front Oncol. 2021;11:696732.","journal-title":"Front Oncol"},{"issue":"4","key":"2833_CR19","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jmig.2019.08.002","volume":"27","author":"R Wang","year":"2020","unstructured":"Wang R, Tao X, Wu X, Jiang H, Xia H. Number of removed pelvic lymph nodes as a prognostic marker in FIGO Stage IB1 Cervical Cancer with negative lymph nodes. J Minim Invasive Gynecol. 2020;27(4):946\u201352.","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"2833_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ygyno.2016.11.038","volume":"144","author":"D Nasioudis","year":"2017","unstructured":"Nasioudis D, Chapman-Davis E, Witkin SS, Holcomb K. Prognostic significance of lymphadenectomy and prevalence of lymph node Metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. Gynecol Oncol. 2017;144(2):414\u20139.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2833_CR21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00404-020-05724-x","volume":"302","author":"F Frenzel","year":"2020","unstructured":"Frenzel F, Hollaender S, Fries P, Stroeder R, Stroeder J. Jejunal obstruction due to rare internal hernia between skeletonized external iliac artery and vein as late complication of laparoscopic hysterectomy with pelvic lymphadenectomy-case report and review of literature. Arch Gynecol Obstet. 2020;302(5):1075\u201380.","journal-title":"Arch Gynecol Obstet"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02833-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02833-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02833-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:02:38Z","timestamp":1703163758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02833-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2833"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02833-y","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from the approval processes of the Institutional Review Boards because the SEER database patient information is de-identified. The need for written informed consent was waived for The SEER Dataset was a public-use dataset.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (NA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"681"}}